Apyx Medical Q2 FY26 net loss narrows to $3.2 million; revenue rises 22.1% to $13.9 million vs year ago
APYX•Product clearance and outlook
- Expanded FDA 510(k) clearance added power liposuction for AYON; limited launch began, with initial commercial shipments in June 2026.
- Apyx reaffirmed its FY2026 revenue outlook of $59 million-$60 million, including Surgical Aesthetics of $54 million-$55 million and OEM of about $5 million.
Q2 revenue and profitability improve
- Apyx Medical posted Q2 2026 revenue up 22.1% to $13.9 million, led by Surgical Aesthetics up 28.1% to $12.4 million.
- Net loss attributable to stockholders narrowed to $3.2 million; loss per share improved to $0.07.
- Adjusted EBITDA loss (non-GAAP) narrowed to $0.7 million as gross margin rose 1.6 percentage points to 63.9%.
